January 07, 2015
2 min read
Save

Retinal hemangioblastoma size, location affect tumor regression

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The efficacy of treatment for retinal hemangioblastoma hinges on tumor size and location, according to a study.

Perspective from Carol L. Shields, MD

The retrospective case series included 37 eyes of 32 patients with retinal hemangioblastomas.

Seventy-three tumors were identified in the 37 eyes. Seven (9.6%) were identified in the juxtapapillary area, and 66 (90.4%) were identified in the peripheral area.

Small tumors less than 0.5 mm underwent laser photocoagulation. Moderate-size tumors that were 0.5 mm to 3 mm underwent transpupillary thermotherapy. Large tumors greater than 3 mm underwent combined transpupillary thermotherapy and cryotherapy.

Mean follow-up was 33.6 months.

After treatment, 90% of small tumors and 66.7% of large tumors regressed; the between-group difference was statistically significant (P = .044).

Peripheral tumors responded significantly better to treatment than juxtapapillary tumors (P = .010).

Size and location of tumors were the only factors that significantly affected tumor regression.

Five eyes (14%) experienced treatment-related complications; one-step combination therapy was used more frequently in eyes with complications (P = .048).

Poor baseline visual acuity correlated significantly with poor visual outcome (P < .001).

Tumors of patients with good baseline best corrected visual acuity of 20/50 or better typically showed greater regression than those of patients with poor baseline BCVA of 20/400 or worse, but the difference was not significant.

Disclosure: The authors have no relevant financial disclosures.